Project: A novel, topical drug for treatment of diabetic foot infections (DFI)

We want to provide solid evidence of the clinical efficacy of LTX-109 in treatment of infections in diabetic foot ulcers, which is a debilitating medical condition with a large unmet need. The effect of this novel, topical antimicrobial drug will be demonstrated in a Phase II proof-of-concept study in patients with mild diabetic foot ulcers. The drug development will be accomplished in collaboration with other European SMEs.

Acronym CureDFI (Reference Number: 9146)
Duration 01/10/2014 - 01/03/2016
Project Topic Biological Sciences / Technologies
Network Eurostars 2
Call Eurostars Cut-Off 1

Project partner

Number Name Role Country
19687 Lytix Biopharma AS Coordinator Norway
19688 Smerud Medical Research UK Ltd Partner United Kingdom
19689 MedPharm Ltd Partner United Kingdom
19690 CTC Clinical Trial Consultants AB Partner Sweden